Indian equities lost momentum after a positive start, with Nifty closing lower and broader markets declining sharply. Investor caution ahea...

Indian equities ended higher on Tuesday, supported by easing geopolitical tensions and softer crude prices. A sharp drop in India VIX boost...

The Bengaluru-based firm said the new vehicle will invest between $500,000 and $3 million in IP-led firms across these sectors. The launch ...

R Mukundan, CEO of Tata Chemicals, has assumed the presidency of the Confederation of Indian Industry (CII) for 2026-27, succeeding Rajiv M...

Indian vaccine developer Bharat Biotech International Ltd. is considering an initial public offering that may raise more than $500 million,...

MTBVAC, the TB vaccine, has undergone Phase I and II clinical trials in India. The vaccine has demonstrated safety and immunogenicity. Base...

Bharat Biotech has partnered with Alopexx, Inc. to co-develop and commercialize the anti-microbial vaccine AV0328 in India and other low-in...

Bharat Biotech unveiled Hillchol, a new single-strain oral cholera vaccine, developed with Hilleman Laboratories. Addressing the high globa...

Responding to Trinamool Congress member Sougata Roy, who had asked whether the government took any punitive action against the company for ...

Japan has included Bharat Biotech's Covaxin in the list of recognised vaccines, a move aimed at facilitating travel between the two countri...

"This represents one of the first approvals worldwide for COVID-19 vaccines for the 2-18 age group. Bharat Biotech sincerely thanks the DCG...

The latest 'Status of COVID-19 vaccines within WHO EUL/PQ evaluation process' guidance document dated September 29 on the WHO website said ...

Bharat Biotech intends to submit documentation for emergency use authorisation to several additional countries worldwide, the company said.

Bharat Biotech's pre-submission meeting has been scheduled on June 23 for evaluation of the World Health Organisation (WHO)'s Emergency Use...

The indigenous, inactivated vaccine is being developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio-containment faci...

Bharat Biotech has signed up 13,000 volunteers for the Phase 3 trial, backed by India's government medical research body, and is progressin...

"This is India's first phase-III efficacy study for a Covid-19 vaccine, and the largest phase-III efficacy trial ever conducted in India," ...